What is Landsdowne Labs?
Landsdowne Labs operates at the intersection of hard tech and medical innovation, emerging as a high-impact spinout from the renowned Langer Lab. The company is primarily focused on the commercialization of ChildLok, a proprietary technology engineered to deactivate button batteries upon accidental ingestion. By providing a turnkey safety solution for global battery manufacturers, Landsdowne Labs addresses a significant public health crisis. Their market position is defined by a commitment to integrating advanced materials into consumer electronics, effectively bridging the gap between laboratory research and industrial-scale safety standards.
How much funding has Landsdowne Labs raised?
Landsdowne Labs has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Landsdowne Labs
PPP
Public-Private Partnership
What's next for Landsdowne Labs?
With this late-stage capital, Landsdowne Labs is poised to accelerate the adoption of its safety protocols across the global battery supply chain. The strategic roadmap likely involves expanding manufacturing partnerships and navigating regulatory landscapes to ensure ChildLok becomes the industry standard for battery safety. As the company transitions from development to widespread commercial deployment, the focus will shift toward operational efficiency and securing long-term licensing agreements with major electronics firms. This phase of growth is critical for establishing the company as a leader in the medical technology and materials science sectors, ensuring that their innovations achieve the necessary scale to impact global health outcomes significantly.
See full Landsdowne Labs company page
